Elan Pharma International Limited v. Abraxis Bioscience Inc.
1:06-cv-00438
Overview
Parties
Counter Claimant
Counter Defendant
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 17 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,399,363 A Asserted | US Continuation / Sibling | View Official Patent → |
| π¨π¦ Canada | CA 002098242 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2098242 C | Canada Counterpart | View Official Patent → |
| π©πͺ Germany | DE 69328136 T | Germany Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 93,201,883 A | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 577,215 B1 | European Counterpart (EP) | View Official Patent → |
| π―π΅ Japan | JP 5158808 A | Japan Counterpart | View Official Patent → |
| π°π· South Korea | KR 1019930012 | South Korea Counterpart | View Official Patent → |
| π°π· South Korea | KR 940001881 A | South Korea Counterpart | View Official Patent → |
| π¨π³ China | CN 93108050 A | China Counterpart | View Official Patent → |
| π¨π³ China | CN 1063630 C | China Counterpart | View Official Patent → |
| πΊπΈ United States | US 5,494,683 A | US Continuation / Sibling | View Official Patent → |
| π―π΅ Japan | JP 2008138475 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 4709873 B2 | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2010186927 A | Japan Counterpart | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5399363
Surface modified anticancer nanoparticles
|
Filed: 1992-07-01
Issued: 1995-03-21
|
Expired (Term Ended)
Expires: 2012-07-01
|
|
|
US5834025
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
Filed: 1996-08-14
Issued: 1998-11-10
|
Expired (Term Ended)
Expires: 2016-08-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
135
Dispositive
11
Granted
4
Denied
5
Pending / Review
125
Motions by Category
Key Dispositive Motions & Rulings